"2026年第一批广西科技计划拟立项项目名单出来了，'铁捕快'在里面！"12月21日，刚碰面，"铁捕 快"团队负责人、广西医科大学第一附属医院放射科副主任彭鹏便给记者分享了这个好消息。 彭鹏所说的"铁捕快"，是一个基于磁共振影像智能化评估地中海贫血（以下简称"地贫"）心、肝脏 铁含量系统。今年9月，该系统在2025年数智健康创新应用大赛上荣获一等奖。 "铁捕快"何以实现"捕铁快"？关键在于AI。 "有了AI，医生不用手动勾画检测区域，检测时间从原来的5—10分钟大幅缩短至2秒，还能根据影 像数据直接计算铁浓度数值。"彭鹏介绍，目前系统自动识别并勾画检测区域的准确率极高，避免了人 工操作产生的主观误差，既建立了标准化的评估流程，也显著提升了诊断准确率。同时，整体费用较国 外软件下降约三分之二，切实减轻了地贫患者长期检查的经济负担。 当前，这一技术正通过远程诊断惠及更多患者。前不久，地贫患者孙先生在桂林一家医院完成磁共 振扫描后，其影像数据便通过系统传送至广西医科大一附院。借助"铁捕快"，阅片医生远程调阅并分析 后，即可出具一份专业的影像诊断报告单回传至孙先生所在的医院。整个过程，数据在"跑"，专家 在"看"，而 ...

Core Viewpoint - Jindalai (688057) experienced a significant stock price increase, opening up by 8.79% and reaching a peak increase of over 11% on December 22, 2023, following announcements of capital increases in two medical technology companies [1] Group 1: Company Actions - Jindalai announced plans to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., acquiring a 34% stake in the company [1] - The company also plans to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., resulting in a 10% ownership stake [1] Group 2: Business Focus of Invested Companies - Yunnan Jici Medical focuses on the research and application of autologous cell technology [1] - Beijing Zhongke Hongtai specializes in the research, production, and sales of medical robotics technology and systems [1]

Group 1 - The core viewpoint of the news is that Xin Kai Yuan has shown significant trading activity, with a financing net purchase of 1.86 million yuan on December 19, indicating strong investor interest [1] - As of December 19, the total margin trading balance of Xin Kai Yuan is 862 million yuan, which accounts for 10.74% of its market capitalization, indicating a high level of leverage compared to the past year [1] - The company has a low short-selling balance of 232,900 yuan, with a short-selling volume of 14,100 shares, suggesting limited bearish sentiment among investors [1] Group 2 - Xin Kai Yuan Medical Technology Group Co., Ltd. was established on March 13, 2003, and listed on August 25, 2010, focusing on the research, production, and sales of high-value pharmaceutical excipients and diagnostic services [2] - The company's revenue composition includes PVP other (39.57%), PVPK30 powder (28.35%), and other segments, with a total revenue of 951 million yuan for the first nine months of 2025, reflecting a year-on-year decrease of 14.36% [2] - The net profit attributable to the parent company for the same period is 201 million yuan, down 35.39% year-on-year [2] Group 3 - Xin Kai Yuan has distributed a total of 900 million yuan in dividends since its A-share listing, with 607 million yuan distributed over the past three years [3]

Core Viewpoint - Hubei province is experiencing significant technological innovation and development, characterized by rapid market capture and long-term strategic planning, showcasing a strong momentum in scientific and technological advancements [1][3]. Group 1: Technological Innovation - Hubei's "cutting-edge" technology initiative has led to the rapid development of advanced medical devices, such as a multi-modal imaging surgical robot, which was developed in just three years, significantly faster than similar products [3][4]. - The province has successfully addressed 981 key technological needs, resulting in 42 achievements, with 60% reaching international advanced levels and 20% leading globally [4]. - Hubei's innovation ecosystem includes over 200 research institutions and leading enterprises collaborating on targeted breakthroughs [4]. Group 2: Support for Startups - Hubei's approach to nurturing tech companies involves a comprehensive lifecycle support system, providing tailored resources for each stage of development, from seed to maturity [5]. - The establishment of a supportive environment has allowed startups, such as Opal Biotechnology, to rapidly progress from project initiation to operational status within months [5]. Group 3: Long-term Commitment - Hubei emphasizes the importance of long-term foundational research, with a focus on revolutionary technologies that require sustained investment and commitment [6][7]. - The province has a history of consistent investment in technology, with over 30 years of dedicated funding leading to the establishment of a robust scientific research infrastructure [6]. Group 4: Research and Development Achievements - Significant breakthroughs in various fields, such as high-resolution remote sensing satellites and innovative agricultural products, have been achieved through persistent research efforts [9][18]. - Hubei has developed hundreds of pilot testing platforms to facilitate the commercialization of research outcomes, ensuring that innovations can be effectively translated into market-ready products [12][10]. Group 5: Financial and Institutional Support - The province has implemented reforms to clarify ownership of scientific achievements, encouraging researchers to commercialize their work without fear of losing state assets [16]. - Innovative financial services, such as credit loans based on innovation scores, have been introduced to alleviate funding challenges faced by tech companies [17]. Group 6: Future Prospects - Hubei's commitment to integrating technology into various sectors, including agriculture and manufacturing, is expected to drive economic growth, with projections indicating a crossing of the 6 trillion yuan threshold in economic output [21]. - The province is positioning itself as a leader in advanced manufacturing and smart city development, with significant investments in sectors like automotive and optical communications [20].

本届大会上，海医汇集中发布了10余项技术，覆盖血液与健康生态、细胞与基因治疗、高端科研仪器、 罕见病诊疗、脑重大疾病防治及AI+重大疾病防治等多个前沿领域。同时，海医汇携手生态伙伴于本届 大会上发起"汇聚AI智慧，促进医疗共融共创新范式"倡议，旨在以AI技术驱动科研范式变革，共同推动 AI技术在医疗健康领域的深度融合与转化应用，加速科技创新成果从实验室走向临床普惠。 此外，海尔盈康一生与首都医科大学再度携手，于本届大会上启动"科创菁英培育计划"二期，将进一步 拓展合作广度与培育深度，共同搭建贯通"基础-临床-转化"的协同培育体系，助力更多青年科研人才 将"想法"转化为"成果"。 12月19日，以"Al for Health·助力健康中国2030"为主题的第二届海医汇医疗科技创新生态大会在北京召 开。本届大会由中国研究型医院学会、中国医学科学院北京协和医学院、广州实验室主办，海医汇承 办，北京脑重大疾病研究院为支持单位，《医师报》社为战略支持媒体。大会汇聚知名院士、专家学者 及行业领军企业代表，共同探讨在AI与科技驱动下，跨越从基础研究到产业应用的"达尔文之海"，构建 科研与产业协同新范式，为医疗健康领域新质生 ...

金达莱12月21日公告，公司拟使用自有资金3000万元向北京中科鸿泰医疗科技有限公司增资，其中 195.86895万元用于认购中科鸿泰195.86895万元的新增注册资本，剩余2804.13105万元计入资本公积。 本次交易完成后，公司将持有中科鸿泰10.00%的股权。 本次对外投资事项已经公司内部审议程序批准，无需提交董事会、股东会审议通过，亦不需要有关部门 批准。本次对外投资不构成《上市公司重大资产重组管理办法》规定的重大资产重组，亦不构成关联交 易。 ...

Core Viewpoint - The company intends to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake, which has been approved internally and does not constitute a major asset restructuring or related party transaction [1] Group 1: Investment Details - The investment amount is 30 million yuan [1] - After the investment, the company will hold a 10% equity stake in Zhongke Hongtai [1] - The investment has received internal approval from the company [1] Group 2: Company Background - Zhongke Hongtai was founded by Professor Hou Zengguang's team and has strong research capabilities in the field of medical artificial intelligence [1] - The company's products have entered the special review process for innovative medical devices by the National Medical Products Administration [1] Group 3: Financial Performance - As of January to September 2025, Zhongke Hongtai reported revenue of 10.26 thousand yuan and a net loss of 550.77 thousand yuan [1] - The company is currently not profitable, indicating uncertainty in future operating performance and investment returns [1]

Core Viewpoint - The article discusses the development of the Hengqin Guangdong-Macao Deep Cooperation Zone, emphasizing the integration of Macao's resources with Hengqin's industrial capabilities to foster economic diversification and innovation. Group 1: Economic Development - In the first three quarters of the year, the value added of the "four new" industries in the cooperation zone reached 25.964 billion, a year-on-year increase of 14.6%, accounting for 66.1% of the GDP [1] - The cooperation zone aims to promote Macao's economic diversification through the "Macao + Hengqin" model, focusing on collaboration in technology, manufacturing, and finance [1] Group 2: Industry Collaboration - The cooperation between Macao universities and companies like Osen Technology is crucial for innovation, exemplified by the establishment of a joint laboratory for brain-machine interfaces [4] - Osen Technology's AI acoustic detection technology is being utilized in major industries such as consumer electronics and new energy vehicles, showcasing the practical application of research [2] Group 3: Healthcare Innovations - The Guangdong Zhenjiankang Medical Technology Company, a representative of the "Macao R&D + Hengqin Transformation" model, has successfully completed over 5,000 clinical surgeries with its robotic technology [5] - The company is part of a broader initiative to support rapid growth and capability enhancement for enterprises in the cooperation zone [5] Group 4: Pharmaceutical Development - Qiwei Biotechnology is advancing new drug development, with its innovative traditional Chinese medicine entering phase III clinical trials, benefiting from the cooperation zone's policies [7] - The company has submitted multiple drug manufacturing applications, with several already approved by the Macao health authorities, highlighting the regulatory advantages of the cooperation zone [9] Group 5: Talent Attraction and Entrepreneurship - The establishment of companies like Deep Translation Technology in Hengqin illustrates the successful attraction of talent from Macao universities, contributing to the local economy [10] - The cooperation zone is creating a new industrial development model that integrates Macao's platform with international resources and Hengqin's space for innovation [13]

12月19日，盈康生命科技股份有限公司在北京举办"AI肿瘤全周期健康管理发展论坛"。论坛聚焦人工智能赋能肿瘤防治体系变革，来自政策研究、临 床医学、科技企业及产业投资等多领域的专家学者与生态伙伴，共同探讨AI驱动下肿瘤防控新模式的构建。 与传统的互联网医院模式和线下医院的数字化升级不同，盈康生命肿瘤全周期健康管理智能体真正实现了线上线下的融合，形成了肿瘤全周期健康管 理的新业态。 据了解，盈康生命旗下医院每年服务近20万肿瘤患者。目前，我国肿瘤防治事业面临的系统性挑战，同时叠加人口老龄化趋势，社会对肿瘤长期、连 续照护的需求日益迫切。因而，突破传统以医院为中心的"片段化"诊疗模式，构建覆盖预防、诊断、治疗、康复全周期的系统性新范式已成为行业共 识。 自2025年4月发布AI创新应用平台后，肿瘤健康管理智能体的发布也标志着盈康生命AI战略的再升级，即从AI工具到场景产品的升级。依托该智能 体，盈康生命将于2026年正式对外发布肿瘤垂直领域的APP，未来三到五年预计服务百万计用户量，并围绕患者、医生及药械企业需求开发生态服务 产品，实现生态闭环。 财经频道更多独家策划、专家专栏，免费查阅>>责任编辑：栎树 （盈康 ...

格隆汇12月21日｜据浙江发布，12月20日，国家人工智能应用中试基地(医疗)·浙江年度系列重大成果发 布，基地产业园开园，基地服务平台正式对外服务。 作为国家"人工智能+"行动和"两重"战略的重大布 局，基地将坚决扛起国家使命，锚定"国际一流"，围绕"1+5+6+N"总体架构，全力打造"人工智能+医疗 健康"中试验证、行业应用、产业生态三大高地，让医学人工智能成为创新浙江最鲜明的行业标识。 ...